Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgments

Executive Summary

Rep. Henry Waxman (D-Calif.) is developing generic drug reform legislation that would eliminate the 30-month stay of approvals on ANDAs subject to patent litigation

You may also be interested in...



FDA Patent Listing Review System Suggested By Paxil Appeals Court

An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4

GPhA Eyes Trade Deals As Vehicle For U.S. Waxman/Hatch Reform

The Generic Pharmaceutical Association could use negotiations for free trade agreements as an opportunity to enact changes in U.S. Waxman/Hatch provisions, consultant Fabiana Jorge (MFJ International) told the GPhA annual meeting

FDA Patent Listing Review System Suggested By Paxil Appeals Court

An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4

Related Content

UsernamePublicRestriction

Register

PS041221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel